NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
ZURICH, Jan. 12, 2026 /PRNewswire/ — NewcelX Ltd. (Nasdaq: NCEL) (“NewcelX” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research…